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Chronic kidney disease (CKD) is increasingly recognized as a
global public health problem. There is now convincing
evidence that CKD can be detected using simple laboratory
tests, and that treatment can prevent or delay complications
of decreased kidney function, slow the progression of kidney
disease, and reduce the risk of cardiovascular disease (CVD).
Translating these advances to simple and applicable public
health measures must be adopted as a goal worldwide.
Understanding the relationship between CKD and other
chronic diseases is important to developing a public health
policy to improve outcomes. The 2004 Kidney Disease
Improving Global Outcomes (KDIGO) Controversies
Conference on ‘Definition and Classification of Chronic
Kidney Disease’ represented an important endorsement of
the Kidney Disease Outcome Quality Initiative definition and
classification of CKD by the international community. The
2006 KDIGO Controversies Conference on CKD was convened
to consider six major topics: (1) CKD classification, (2) CKD
screening and surveillance, (3) public policy for CKD, (4) CVD
and CVD risk factors as risk factors for development and
progression of CKD, (5) association of CKD with chronic
infections, and (6) association of CKD with cancer. This report
contains the recommendations from the meeting. It has been
reviewed by the conference participants and approved as
position statement by the KDIGO Board of Directors. KDIGO
will work in collaboration with international and national
public health organizations to facilitate implementation of
these recommendations.
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Chronic kidney disease (CKD) is increasingly recognized as a
global public health problem. The declaration of World
Kidney Day to be observed annually beginning in March
2006 sends a clear message to the public, government health
officials, physicians, allied health professionals, patients, and
families that ‘CKD is common, harmful, and treatable’.1 The
recognition of CKD as a public health problem has evolved,
in part, from the acceptance of the conceptual model,
definition, and classification of CKD proposed by the
National Kidney Foundation Kidney Disease Outcome
Quality Initiative in 2002 and modified by Kidney Disease
Improving Global Outcomes (KDIGO) in 20042–4 (Figure 1;
Tables 1 and 2). As a result, physicians, investigators, and
public health officials across the world can now more easily
ascertain CKD irrespective of cause, study its antecedents and
outcomes, determine risk factors for its development and
progression, and develop strategies for its detection, evalua-
tion, and treatment.
In the US, 9.6% of non-institutionalized adults are
estimated to have CKD.5,6 Studies from Europe, Australia,
and Asia confirm the high prevalence of CKD.7–10 Outcomes
of CKD include not only progression to kidney failure but
also complications of reduced kidney function and increased
risk of cardiovascular disease (CVD). Patients with CKD are
far more likely to die, principally from CVD, than to develop
kidney failure.11 There is now convincing evidence that CKD
can be detected using simple laboratory tests, and that certain
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treatments can prevent or delay complications of decreased
kidney function, slow the progression of kidney disease, and
reduce its associated CVD risk.2,12–18 Translating these
advances to simple and applicable public health measures
must be adopted as a goal worldwide. Although there is still
much to learn about the impact of treatments and their
optimal combinations for CKD, it is not too early to begin
implementation.
Chronic diseases are now the leading causes of death
worldwide. The World Health Organization (WHO) esti-
mates that there were approximately 58 million deaths
worldwide in 2005, with 35 million attributed to chronic
disease.19,20 In developed countries and lower-middle-
income developing nations, CVD and cancer were the
leading causes of death. In low-income developing countries,
infections remained the leading cause of death, but chronic
non-communicable diseases were on the rise. The WHO
report called for governments to provide leadership in
addressing the projected continued increase in deaths due
to chronic diseases.
While CKD is not mentioned in the 2005 WHO report,19
it is now recognized that CKD is common in people with
CVD and with CVD risk factors, and that CKD multiplies the
risk for adverse outcomes in these conditions.17 CKD is also
reported to be a risk factor for adverse outcomes in other
chronic diseases such as infections and cancer,21 and should
be studied in more detail. Understanding the relationship
between CKD and other chronic diseases is important to
develop a public health policy to improve outcomes
(Figure 2).
SCOPE
KDIGO is an independent non-profit foundation governed
by an international Board of Directors with the stated
mission to ‘improve the care and outcomes of kidney disease
patients worldwide through promoting coordination, colla-
boration and integration of initiatives to develop and
implement clinical practice guidelines’.22 The KDIGO Con-
troversies Conference on ‘Definition and Classification of
Chronic Kidney Disease’ was held in Amsterdam in
November 2004, attended by an international group of
experts, represented an important endorsement of the Kidney
Disease Outcome Quality Initiative definition and classifica-
tion of CKD by the international community.4 In 2006,
KDIGO convened another Controversies Conference to build
on and extend the recommendations of the 2004 conference.
The agenda, selected presentations, and abstracts of the
meeting are posted on the KDIGO website (http://www.
kdigo.org/content-cconf.htm#Public%20Health). Specifically,
the conference addressed two major topics.
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Figure 1 | Conceptual model of the course of chronic kidney
disease and therapeutic strategies. Shaded ellipses represent
stages of CKD; unshaded ellipses represent potential antecedents or
consequences of chronic kidney disease. Thick arrows between
ellipses represent risk factors associated with the initiation and
progression of disease that can be affected or detected by
interventions. Interventions for each stage are given beneath the
stage. ‘Complications’ refer to all complications of chronic kidney
disease and its treatment, including complications of decreased GFR
(hypertension, anemia, malnutrition, bone, and mineral disease) and
cardiovascular disease. Increasing thickness of arrows connecting
later stages to complications represents the increased risk of
complications as kidney disease progresses. Modified and reprinted
with permission.2–4
Table 1 | KDIGO definition of CKD
Structural or functional abnormalities of the kidneys forX3 months, as
manifested by
1. Kidney damage, with or without decreased GFR, as defined by
Pathologic abnormalities
Markers of kidney damage
Urinary abnormalities (proteinuria)
Blood abnormalities (renal tubular syndromes)
Imaging abnormalities
Kidney transplantation
2. GFR o60 ml/min/1.73 m2, with or without kidney damage
CKD, chronic kidney disease; GFR, glomerular filtration rate; KDIGO, Kidney Disease
Improving Global Outcomes.
Table 2 | Current CKD classification based on severity and therapy
Stage Description GFR (ml/min/1.73 m2) ICD-9 CM code Treatment
1 Kidney damage with normal or m GFR X90 585.1
2 Kidney damage with mild k GFR 60–89 585.2 1–5 T if kidney transplant recipient
3 Moderate k GFR 30–59 585.3
4 Severe k GFR 15–29 585.4
5 Kidney failure o15 (or dialysis) 585.5
585.6 (if ESRD) V codes for dialysis
or transplantation
5D if dialysis (HD or PD)
CKD, chronic kidney disease; GFR, glomerular filtration rate; m, increased; k, decreased.
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Classification, surveillance, and public policy for CKD
The plenary session included presentations on CKD screen-
ing and surveillance, standardization of creatinine measure-
ment, experience in measuring and reporting the estimated
glomerular filtration rate (eGFR), implementation of albu-
minuria testing, revisions to the ninth International Classi-
fication of Disease, and public policy initiatives. Breakout
sessions focused on CKD classification (group 1), CKD
screening and surveillance (group 2), CKD, and public policy
(group 3).
Associations of CKD with chronic diseases
The plenary session included presentations on the WHO
perspective on chronic disease, and on associations of CKD
with other chronic diseases: CVD, infections, and cancer. The
model for assembling evidence to evaluate and classify CKD
as a risk factor for CVD (Table 3) was the paradigm used for
evaluating the association of CKD with other chronic
diseases. Breakout groups focused on CVD risk factors and
CVD as risk factors for CKD development and progression
(group 4), and CKD as a risk factor for adverse outcomes of
chronic infections (group 5) and of cancer (group 6).
Each breakout group was asked to formulate both clinical
and research recommendations based on evidence and
opinion. The groups did not perform a systematic review
or grading of available evidence. This report contains the
recommendations made at the meeting and has been
reviewed by the conference participants (Appendix) and
approved as position statement by the KDIGO Board of
Directors. These recommendations will be pursued by the
KDIGO Board with the World Health Organization and
other international and national public health organizations.
RECOMMENDATIONS FROM THE BREAKOUT GROUPS
Group 1: Classification of CKD
CKD is a heterogeneous condition, whose clinical manifesta-
tions and course depend on the cause and type (pathology),
severity, rate of progression, and comorbid conditions. The
group examined the need to refine the CKD classification to
include additional clinical information, to evaluate the utility
of adopting a coding system, which subdivides CKD by
presumed cause, and to identify key research questions that
would facilitate or improve the understanding and applica-
tion of the CKD classifications system worldwide. The
rationale for the recommendations is that development and
adoption of a consistent framework for classification of CKD
will facilitate international collaborations and allow for
scientific discoveries to be more readily adopted worldwide.
Recommendations
K KDIGO should not change the existing classification at this
time. The classification system endorsed by KDIGO in
2004 includes severity and modality of treatment for
kidney failure (Table 2). It is acknowledged that
additional clinical information (Table 4) is required for
the evaluation and management of individual cases of
CKD. However, the potential benefits of adding informa-
tion was thought to be outweighed by the disadvantages
of increased complexity and incomplete description of an
essentially heterogeneous condition. The current classifi-
cation system was deemed to be clear, simple, and useful,
as evidenced by its ongoing endorsement and adoption
worldwide. Moreover, there was concern that further
additions would detract from the attempt to maintain a
simple message applicable across various disciplines and
communities. There was discussion of whether albumi-
nuria is a marker of kidney damage in non-diabetic as
well as diabetic kidney disease. Data from the Heart
Outcomes and Prevention Evaluation Study indicate that
‘microalbuminuria’ was associated with same relative risk
for progression to ‘clinical proteinuria’ in non-diabetic
and diabetic kidney diseases,23 suggesting that the current
threshold for albuminuria as a marker of kidney damage
(a spot urine albumin-to-creatinine ratio 430 mg/g) is
applicable to diabetic and non-diabetic kidney diseases.
K KDIGO should work with the WHO to adopt the USA
modifications to ICD-9 CM and in updates to ICD-10 and
subsequent revisions. It is important that coding systems
capture the elements of the current classification system.
The ninth version of the International Classification of
Disease in the USA (ICD-9 CM) has adopted a revised
coding system that incorporates the current CKD staging
system. There was consensus that current (version 10)
and future (version 11) iterations of ICD should
incorporate and maintain this coding system so that
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Figure 2 | Relationship of chronic kidney disease to chronic
diseases. Among patients with chronic diseases, for example,
cardiovascular disease, infectious diseases, or cancer, presence of
chronic kidney disease is associated with an increased risk of
complications related to those diseases.
Table 3 | Approach to evaluation of CKD as a risk factor for
CVD in CVD risk factor conditions
CVD risk
factor
CKD
prevalence
CKD as a risk factor
for CVD morbidity
CKD as a risk factor
for CVD mortality
Hypertension m m m
Diabetes m m m
Dyslipidemia m m m
CKD, chronic kidney disease; CVD, cardiovascular disease; m, increased.
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more epidemiologic information could be gained from
administrative data. Healthcare providers in different
countries have variable familiarity with these codes.
Nonetheless, each country does have a system of coding
and variable obligations for reporting. The consistency of
evolving iterations of ICD is essential for following trends
over time, and potentially for cross country comparisons,
as well as providing essential information to regional
public health authorities.
K KDIGO should facilitate the development of a uniform
‘essential data set’ for description of CKD for coding
purposes. There is a need to describe an essential data set
for coding to ensure that a minimal amount of data is
obtained on all patients identified as having CKD.
Although no final recommendations were made, key
elements could include the information provided in
Table 4. For research purposes, the inclusion of race,
ethnicity, socio-economic status, and level of education
would improve understanding the impact of CKD
worldwide.
Research recommendations
K Research recommendations from the 2004 KDIGO con-
ference on definition and classification of CKD remain high
priority.4
K Additional studies are needed to:
K Define the societal and individual implications of
over- and underdiagnosis of CKD. This should
include analysis of the impact of health behaviors,
and evaluation of the costs of testing, labeling, and
resource utilization in different countries.
K Systematically analyze the performance of current
GFR estimating equations in different populations
and their use:
– for some specific testing or treatment strate-
gies, such as frequency of testing for complica-
tions or for drug dosing
– in special patient populations such as patients
with reductions in kidney mass due to surgery
or a past history of acute kidney injury
– in chronic diseases, due to concerns about
muscle wasting and malnutrition (see reports
by groups 5 and 6).
K Identify new markers of kidney damage and new filtration
markers (for example cystatin C) and analyze their
performance in different patient populations.
Group 2: Screening and surveillance
The group discussed strategies for implementation of
screening and surveillance for CKD in developed and
developing countries. Screening is an activity, whereby
persons in a defined population who are not aware of CKD
are tested to detect the disease and, if present, are
subsequently treated to reduce the risk of progression of
CKD and its complications. Surveillance refers to an activity
to provide key information on CKD, such as time, location,
magnitude, and severity, in order to guide implementation of
medical and public health measures to control progression of
CKD and its complications.
It is not known whether screening the general population
would be cost-effective.24,25 Targeted screening should be
directed at subgroups of the population who would derive
the most benefit from CKD detection. Among developed and
developing nations, the risk for CKD is increased in people
with CVD risk factors or established CVD, in whom CKD
multiplies the risk for adverse outcomes of CVD. Thus, the
‘CKD subgroup’ of patients with CVD and CVD risk factors
constitutes a high-risk group requiring special attention.2 As
discussed by groups 5 and 6, patients with some chronic
infectious diseases and cancers may also be at increased risk.
In conditions where the prevalence of CKD is increased and
the risk of complications due to preventable factors is high,
including adjustment of drug doses to avoid toxicity,
screening for CKD may be warranted. In these groups,
screening for CKD could be implemented using existing
infrastructures for the detection of other chronic conditions.
Many countries have registries for patients treated by
dialysis and transplantation. However, these programs over-
look people with severe CKD who die before the onset of
kidney failure or are not treated with dialysis or transplanta-
tion despite the onset of kidney failure. In principle, a
Table 4 | Key elements for description of CKD in clinical
practice
Domain Example
Severity GFR level
Treatment Therapies for causes of kidney disease
Treatment modality for kidney failure
Marker of kidney damage
and severity
Pathologic abnormality
Magnitude of albuminuria/proteinuria
Imaging abnormalities
Cause of kidney disease Diabetic kidney disease
Non-diabetic kidney disease
Glomerular diseases
Tubulointerstitial diseases
Vascular diseases
Cystic diseases
Disease in the kidney transplant
recipient
Presence and severity of
complications
Hypertension
Anemia
Malnutrition
Bone and mineral disease
Presence and severity of Diabetes
comorbid conditions Cardiovascular disease
Chronic infections
Cancer
Prognosis Past history or risk factors for fast
progression
Risk factors for cardiovascular disease
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surveillance program for CKD stages 4 and 5 would enable
countries to monitor the magnitude and the care of this
high-risk, high-cost population, and possibly to reduce both
the risk of progression to kidney failure and the cost of
dialysis and transplantation.2 A surveillance program for
patients with CKD stage 3 would reach many more people
and might be an effective way to lower rates of CVD and
death, especially among the elderly with CVD risk factors or
CVD. However, such a larger surveillance program would
require more resources and the available data to assess the
costs and benefits is incomplete.
Recommendations
K All countries should have a targeted screening program for
CKD (Table 5).
K Target groups should include patients with hypertension,
diabetes and cardiovascular disease. Other groups might
include families of patients with CKD, individuals with
hyperlipidemia, obesity, metabolic syndrome, smokers,
patients treated with potentially nephrotoxic drugs, some
chronic infectious diseases and cancers (see reports from
groups 5 and 6), and age 460 years.
K Tests for CKD screening should include both a urine test for
proteinuria and a blood test for creatinine to estimate GFR.
Tests for proteinuria should be selected and performed
according to local guidelines. (This article refers to tests
for proteinuria as tests for detection of proteinuria,
including tests for albumin only; and tests for albumin-
uria as tests for detection of albumin only.) Verification of
proteinuria would require two out of three positive tests.3
In selected populations with an increased risk for
glomerulonephritis, testing for hematuria should also be
performed. Equations for estimating GFR should be
appropriate for standardization of the serum creatinine
assay and application to majority racial and ethnic groups.
K Frequency of testing should be according to available
guidelines and the target group to be tested. In the absence
of specific recommendations, testing need not be more
frequent than once per year.
K All countries should have a surveillance program for CKD
stages 4–5 and strive to include earlier stages. If possible,
data on risk factors for development and progression of
CKD most relevant for the specific population should be
included. Surveillance for CKD could be incorporated
into existing surveillance programs (such as those for
hypertension, diabetes, cardiovascular diseases, infectious
diseases, and cancer) and data from such programs
should be used for surveillance of CKD risk factors. Data
could be obtained from random samples of the general
population or (possibly) populations receiving medical
care or (ideally) registries of stages 4 and 5 CKD. Data
should be collected at a frequency of every 5–10 years, or
more often, depending on disease dynamics, interven-
tional strategies, and regional resources. Additional
components of a CKD surveillance program could be:
consequences of CKD (mortality), education/awareness
(public and professionals), health system capabilities
(primary and specialty care), quality of care markers
(appropriate treatment/referrals), and health policy goals.
Research recommendations
K Evaluate target groups for screening
K Compare specificity and sensitivity of different screening
tests in various settings, including verification of proteinuria
K Define optimal timing interval for screening and surveil-
lance
K Analyze costs, benefits and risks of screening programs
Group 3: Public policy
The group discussed the need for CKD public policy
programs in developed and developing countries, and steps
to implement them. In some countries, the incidence of
kidney failure due to some types of CKD is stabilizing or
declining, possibly reflecting early detection and treat-
ment.26,27 Although the prevalence of kidney failure varies
substantially throughout the world, the number of patients
and the cost of providing dialysis and transplantation
continue to escalate.26,27 Few countries have policies for
CKD and most are unaware of the high prevalence of CKD,
its contribution to other diseases, or its economic burden.
Prevention, early detection and intervention are the more
cost-effective strategies for CKD.
At the same time, costs for other chronic diseases are
increasing. In developed countries, the care of patients with
hypertension, diabetes and cardiovascular disease consumes a
large fraction of health care resources.27 The epidemic of
obesity is expected to magnify these costs. Developing
countries are now also experiencing the burden of these
non-communicable diseases, even though communicable
diseases are not yet under control. CKD is especially common
in people with other chronic diseases and multiplies the risk
for adverse outcomes and costs. Thus, public health policies
for CKD must be coordinated with existing policies for other
chronic diseases.
Recommendations
K Governments should adopt a public health policy for CKD.
CKD is a key component of a cluster of chronic diseases,
Table 5 | High-risk groups for targeted screening program for
CKD
Highest priority
Hypertension
Diabetes
Cardiovascular disease
To be considered
Older age
Family history of kidney disease
Other cardiovascular disease risk factors
Exposure to toxic drugs
Certain chronic infections
Certain cancers
CKD, chronic kidney disease.
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including hypertension, diabetes, and cardiovascular
disease. Within each of these groups, the CKD population
is the group at highest risk and thus, highest priority for
intensive care and close monitoring. Governments should
partner with non-governmental organizations and in-
dustry (at the regional, national, and international levels)
to support the incorporation of CKD into public health
agendas.
K Governments should support programs for screening and
surveillance of CKD. The program would document the
prevalence, incidence, outcomes, care and education of
the public and health care providers. Specific recommen-
dations for screening and surveillance are contained in
the report by group 2.
K Governments should support a public awareness program
for CKD. The public awareness program should present a
simple message: CKD is common, harmful, and treatable,
and individuals should ‘know their A, B, Cs:’ Albumi-
nuria, Blood Pressure, Cigarette Smoking and Cholester-
ol, Diabetes, Estimated GFR, y’
Group 4: CVD risk factors as risk factors for initiation and
progression of CKD
The group acknowledged the strong evidence that CKD itself
is a risk factor for CVD. The group addressed development
and progression of CKD as an outcome of exposure to CVD
risk factors or the presence of CVD. Treatment recommenda-
tions for lowering CVD risk factor in CKD were not
discussed, as many publications have focused on this
topic.12,14,28
The group reviewed a conceptual model distinguishing
risk factors for development of CKD (initiation and
susceptibility) and progression of CKD to later stages
including kidney failure (Figure 3) and attempted to make
terminology more empirical in describing putative risk
factors relating both to CKD and its outcomes (Table 6).
The concept of a ‘clinical intersection’ between CKD and
CVD was proposed as a ‘high risk state’ for poor health
outcomes.29 Inter-relationships of CKD and CVD include the
following: (1) common risk factors (e.g., older age, diabetes,
hypertension), (2) bidirectional effects of one disease process
on the progression of the other (e.g., renal artery stenosis,
heart failure caused by CKD), (3) adverse effects on one
disease process when investigating the other (e.g., contrast-
induced acute kidney injury complicating angiography), and
(4) treatment biases potentially influenced by both diseases
(e.g., angiotensin converting enzyme inhibitors).
The group addressed specific questions related to CVD
(myocardial infarction, heart failure, etc) and CVD risk
factors (diabetes, hypertension, dyslipidemia, obesity, and
smoking) as risk factors for CKD, and attempted to
distinguish CVD risk factors that were responsible for
susceptibility to CKD from those that might be involved in
initiation and progression. Although potentially useful from
a conceptual standpoint, it was generally agreed that this
distinction is difficult based on existing data. Furthermore,
some risk factors (e.g., hypertension and diabetes) may
operate at all three levels (susceptibility, initiation, progres-
sion) with respect to CKD. The ability to distinguish risk
factors for development from progression in observational
studies has been complicated by the lack of data on
albuminuria or other markers of kidney damage at baseline;
thus it may be difficult to be confident that patients with an
estimated GFR 460 ml/min/1.73 m2 do not have kidney
damage. In order to examine these issues better in future
observational studies, it was recommended to classify risk
factors as: (1) likely causal mechanism, (2) mechanism
uncertain, or (3) likely to reflect non-causal association.
Research recommendations
K Studies of CKD as an outcome should strive to:
K Incorporate markers of both kidney damage and
function
K Distinguish risk factors for development of CKD as
well as progression to different stages of CKD
K Study the extent to which risk factors are the same or
differ across different kidney diseases
K Include all ages, including children, and ‘special
populations’
K Studies of CKD should include data on CVD risk factors
and events.
K Studies of CVD should include data on the development
and progression of CKD as an important health outcome
(endpoint).
K Studies evaluating the impact of CVD treatments should
include patients with CKD.
Group 5: CKD as a risk factor for infections
The group focused on two topics: screening for CKD in
chronic communicable diseases and vaccination strategies for
CKD. Whereas both acute and chronic infections can
influence the risk of development and progression of
CKD,30–35 little is known of the compounding impact of
CKD on the development and outcome of chronic infections.
Infection is an important cause of morbidity and
mortality among patients with kidney failure, and is the
second leading cause of death following CVD.36–39 Death
Susceptibility
factors
Initiation
factors
Progression
factors
Progression
factors
End-stage
(outcome)
factors
CVD risk factors and CVD
Normal Increased
risk Damage GFR
Kidney
failure
Death
Complications
Figure 3 | Risk factors for development and progression of CKD.
CVD and CVD risk factors are associated with an increased risk of
transitions from one stage of CKD to the next.
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rates due to pneumonia and sepsis are markedly higher in
dialysis patients compared with the general population
(Figure 4).40,41 These observations suggest that CKD may
be a risk-multiplier for acute infectious disease-associated
mortality, as it is for CVD.
The course of chronic infectious diseases might be
influenced by coexisting CKD. Five infectious diseases,
including the human immunodeficiency virus (HIV),
hepatitis C virus (HCV), hepatitis B virus (HBV), tubercu-
losis, and malaria, are estimated to affect 873 million people
worldwide.42 Table 7 summarizes the prevalence of CKD in
large cohorts of individuals with these chronic infections, and
where known, its association with adverse outcomes.43–51
Several studies, mainly of HIV and HBV infection, have
revealed a strong association of CKD with increased
morbidity and mortality. CKD may increase risk by adversely
affecting the host immune response; alternatively, the
development and progression of CKD may be a marker of
more severe infection.
Many treatment-related issues have not been addressed.
The accuracy of GFR estimating equations has not been
studied well in patients with chronic infectious diseases, in
whom muscle wasting due to malnutrition may confound
estimates based on serum creatinine.52,53 Clinical trials
examining the safety and efficacy of novel anti-infectious
drugs traditionally exclude patients with CKD; this is
particularly true for HCV and HIV infections.54–56
Recommendations
K Screening for CKD in HIV. The guidelines of the Infectious
Diseases Society of America for the management of CKD in
HIV-infected patients recommend screening for kidney
disease at the time of HIV diagnosis.57 Tests should include
(1) a urinalysis (for hematuria and proteinuria) and (2) a
measure of kidney function (creatinine to estimate GFR). If
there is no initial evidence of kidney disease, screening
should be repeated annually. Semi-annual monitoring of
Table 6 | Approach to classification of risk factors for CKD and its outcomes
Risk factor Hypothesized mechanism Observed associationsa
Development of CKD Increase susceptibility to kidney damage Older age, family history of chronic kidney disease, congenital or
acquired reduction in kidney mass, primary hyperfiltration states,
cardiovascular disease, US and European racial or ethnic minority status,
low income or education
Directly initiate kidney damage Diabetes, high blood pressure, obesity, metabolic syndrome,
dyslipidemia, hypercalcemia, autoimmune diseases, systemic infections,
urinary tract infections, nephrolithiasis, urinary tract obstruction, drug
toxicity
Progression of CKD Cause worsening kidney damage and faster
decline in kidney function after initiation of kidney
damage
Types of kidney disease; higher level of proteinuria,
Complications of
CKD
Increase risk for complications of decreased GFR Non-CKD factors related to hypertension, anemia, malnutrition, bone,
and mineral disorders
Accelerate onset or
Recurrence of CVD
Traditional CVD risk factors
Non-traditional ‘CKD-related’ risk factors
Increase morbidity and mortality in kidney failure Low dialysis dose (Kt/V), fluid overload, temporary vascular access,
severe anemia, low serum albumin level, late referral
CKD, chronic kidney disease; CVD, cardiovascular disease; GFR, glomerular filtration rate.
aFor many of the observations, the mechanism underlying their association with CKD is unclear and many of them may be involved at multiple levels in the pathogenesis of
kidney disease and its outcomes. Factors that are implicated in the development, progression and complications of kidney disease are listed in the initial category in which
they could potentially appear.
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Figure 4 | Annual death rates due to sepsis (a) and pulmonary
infections (b) among dialysis patients (black line) compared with
the general population (gray line). The data are stratified by age
and are shown on a logarithmic (a) or an arithmetic (b) scale. This
figure was reproduced with permission.37
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kidney function and urinary markers of kidney damage is
warranted for those receiving long-term drug therapy with
toxicity to the kidney. Table 8 shows the increased risk of
adverse outcomes of HIV infection in patients with
CKD.43–48 Among newly diagnosed patients with HIV,
positive tests for CKD might reflect HIV-associated
nephropathy, other HIV-related glomerular diseases, or
drug-related toxicity,58 but might also be caused by pre-
existing hypertension, diabetes mellitus, or CVD. In
countries with access to highly active anti-retroviral
therapy, the incidence of HIV-associated nephropathy has
declined by almost 75-fold.59 However, in the emerging
chronic disease phase of the AIDS epidemic, long-term
survivors are likely to develop comorbid conditions
including hypertension, diabetes mellitus, and cardiovas-
cular disease. There is also evidence to suggest that the
highly active anti-retroviral therapy-associated metabolic
syndrome might constitute a novel CVD risk factor,
potentially associated with CKD.60,61
K Screening for CKD in HCV. The draft KDIGO clinical
practice guidelines for HCV in CKD recommend screening
for kidney disease at the time of HCV diagnosis and
annually thereafter. Tests should include (1) a urinalysis
(for hematuria and proteinuria) and (2) a measure of
kidney function (serum creatinine to estimate GFR). The
occurrence of glomerular disease in association with
HCV infection is well established,62,63 and population-
level data are now available. A cross-sectional analysis in
the USA demonstrated an association between HCV
seropositivity and albuminuria in people over age 40
years.50 Among individuals older than 60 years, 46% of
HCV-seropositive individuals had albuminuria compared
with 24% of those who were seronegative, but there was
no significant association between HCV seropositivity
and low eGFR. In a cross-sectional study from Taiwan,
non-diabetic subjects who were HCV seropositive had an
8.3% prevalence of X1þ dipstick proteinuria compared
with 5.1% in the seronegative group.51 The impact of
these abnormalities on outcomes remains to be deter-
mined.
K Screening for CKD in other chronic infections. There are
insufficient data to recommend screening for kidney
disease at the time of diagnosing HBV, tuberculosis, and
malaria, particularly Plasmodium malariae. It is acknowl-
edged that acute and chronic phases of these infections
can cause CKD,30–33 that there is potential toxicity to the
kidneys of drugs used to treat them,57 and that
medication dose and frequency adjustments are necessary
for decreased GFR. However, there is insufficient
evidence for screening and no published guidelines on
the optimal timing, frequency or cost–benefit analysis of
screening for CKD in these conditions.
K Vaccination in CKD. All patients with CKD Stage 5D
should be vaccinated for influenza, hepatitis B, and
pneumococcus. The influenza vaccine should be offered
annually. Hepatitis B vaccine should be administered at the
initiation of dialysis and post-vaccine serological testing
should be performed. The pneumococcal vaccine should be
given at least once. Patients with CKD stages 1–4 should
receive the influenza, hepatitis B, and pneumococcal
vaccine if high-risk factors coexist and in accord with
regional immunization guidelines. Recommendations for
organ transplant candidates and recipients were discussed
at a recent KDIGO conference.64 A compilation of
published guidelines from selected countries on the use
of these three vaccines is available on the KDIGO website
(http://www.kdigo.org/ControConf/content-immunization.
htm). The substantial heterogeneity of recommendations
for CKD indicates the need to evaluate the evidence basis
and harmonize immunization guidelines for CKD world-
wide. In the general population, vaccination for these
infections is generally safe and effective. The association
of CKD with impaired host cellular and humoral
immunity can result in suboptimal vaccine-induced
immune response.37,65,66 This calls for the development
of a specialized immunization and monitoring program
for the CKD population. Early vaccination maximizes the
chance of achieving and sustaining immunity,67,68 which
in turn might benefit future kidney transplant recipients.
Further research is needed in CKD stages 1–4 to answer
these important questions.
Research recommendations
K Studies to understand the risk of CKD in patients with HIV,
HCV, HBV, tuberculosis, and Plasmodium malariae:
K Determine the prevalence of CKD.
Table 7 | Proposed approach to CKD as risk factor for adverse outcomes of chronic ID
ID Measure of CKD prevalence CKD as a risk factor for ID morbidity CKD as a risk factor for ID mortality
HIV HIVAN43,44,46,47
Proteinuria44–47
k eGFR48
Yes (AIDS defining illness and hospitalization)
Proteinuria45–47
k eGFR45–47
Yes
Proteinuria44–47
k eGFR48
HCV Proteinuria51
k eGFR50
Unknown Unknown
HBV Proteinuria51 Unknown Probable
k eGFR49
Malaria Unknown Unknown Unknown
TB Unknown Unknown Unknown
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HBV, hepatitis B virus; HCV hepatitis C virus; HIVAN, HIV-associated nephropathy; ID, infectious
diseases. k, decreased.
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K Determine the optimal timing of screening for CKD in
chronic infections, the frequency of testing, the
sensitivity and specificity of screening tests, and the
cost–benefit relationship of this approach.
K Evaluate the accuracy of GFR estimating equations in
persons with chronic infections, with a particular focus
on reducing the influence of confounding factors such
as muscle wasting, malnutrition, and extracellular fluid
volume expansion, particularly, in the setting of
chronic viral liver disease.
K Examine the interaction of coexisting co-infections
with CKD on morbidity and mortality, and the impact
of coexisting co-infections on progression of CKD.
K Studies of the risk of infections and the optimal use of
vaccines in CKD
K Determine the optimal test for the diagnosis of latent
tuberculosis, particularly in endemic areas worldwide.
K Elucidate uremic factors that contribute to impaired
immunity in patients with CKD, hampering effective
immunization.
K Determine the efficacy and cost-effectiveness of
hepatitis B and pneumococcal vaccine in earlier stages
of CKD (e.g., stage 1–4)
K Examine whether due to impaired immunity CKD
patients require a specific immunization program
against highly preventable communicable diseases.
Group 6: CKD as risk factor for adverse outcomes of cancer
The group addressed the assessment of kidney function in
subjects with cancer, occurrence of CKD in parallel to or
secondary to cancer, use of kidney sparing therapies for
kidney cancers, occurrence of cancer in subjects with CKD,
screening for CKD in cancer, screening for cancer in subjects
with CKD, outcomes of cancer treatment in subjects with
CKD.
Assessment of kidney function in subjects with cancer is
essential for dosage adjustment of chemotherapy and for
assessment of treatment toxicities. Even in early stages of
cancer, there may be muscle wasting, which could affect GFR
estimates based on serum creatinine. GFR estimating
equations have been tested with variable results. This
variability may have immediate consequence, as shown in a
report comparing the use of three creatinine-based formulas
in subjects with bladder cancer, in which eligibility for
adjuvant chemotherapy varied many fold according to the
formula that was used.69 Use of the abbreviated modification
of diet in renal disease (MDRD) Study equation has been
recommended by KDIGO, but the US Food and Drug
Administration recommends using the Cockcroft and Gault
formula.70 Studies in cancer patients suggest new formulas
may be more accurate, but they have not been validated and
evaluated adequately.71,72
Table 9 summarizes the prevalence of CKD in individuals
with cancer, and where known, the association of CKD with
adverse outcomes of cancer. Kidney disease occurring in
parallel to or secondary to cancer is well described.
Paraneoplastic membranous glomerulopathy is an acknowl-
edged complication of cancer, but there is only one
quantitative report for this association.73 Reduced GFR in
subjects with cancer has been reported in over half of the
Table 8 | Summary of studies examining the association of CKD with HIV infection
Author (reference) Study design Sample size
CKD predictor
variable Outcome Results (multivariate analyses)
Lewden C (2002)43 Multicenter
prospective
cohort study
(France)
1155 HIV-infected
adults
Baseline and post-
treatment (4-month)
sCr o normal (0.9
(male) or 0.8
(female) mg/dl)
Death At baseline: HR (95% CI) 2.4 (1.3, 4.3)
At 4 months: HR 2.5 (1.0, 6.1)
Gardner LI (2003)44 Prospective
cohort study
(USA)
885 HIV-infected
and 425 at-risk HIV-
negative women
Baseline proteinuria
(X2+) and/or
sCrX1.4 mg/dl
Death HR 2.5 (1.9, 3.3)
Gardner LI (2003)45 Prospective
cohort study
(USA)
885 HIV-infected
adult women
Baseline proteinuria
(X2+) and/or
sCrX1.4 mg/dl
Condition-specific
hospitalizations
Overall hospitalization: HR 1.5 (1.3, 1.8)
Condition-specific hospitalization:
AIDS-defining illness: HR 1.7 (1.1, 2.7)
Kidney conditions: HR 5.0 (2.3, 11.0)
Hepatic conditions: HR 1.8 (1.1, 2.8)
Szczech LA
(2004)46,47
Prospective
cohort study
(USA)
2038 HIV-infected
women
Proteinuria (X1+ on
X2 visits); Inverse
sCr decrease
New AIDS-defining
illness and death
before and after
widespread use of
HAART
AIDS-defining illness
Pre-HAART, proteinuria: HR 1.3 (1.1, 1.6)
Post-HAART, 1/sCrk: HR 1.4 (1.0, 2.1)
Death
Pre-HAART, proteinuria: HR 1.3 (1.1, 1.8)
Pre-HAART, 1/sCrk: HR 1.7 (1.1, 2.7)
Post-HAART, proteinuria: HR 2.2 (1.3, 3.7)
Levin A (2006)48 Prospective
cohort study
(Canada)
2629 HIV-infected
adults initiating
anti-retroviral
therapy
eGFR (MDRD 4-
variable equation)
o 60 ml/min/
1.73 m2
Death eGFR o 60 ml/min/1.73 m2: HR 1.65 (1.01, 2.71)
CI, confidence interval; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HAART, highly active anti-retroviral therapy; HR, hazard ratio; sCr, serum
creatinine.
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subjects in a study from France, but this study did not clearly
distinguish whether reduced GFR was related to the cause or
effects of cancer.74 Kidney disease caused by specific cancers
such as multiple myeloma is well known, but accounts for
less than 1% of patients treated by dialysis in the USA.
Conversely, CKD occurring after chemo- or radiotherapy is
known, but has not been quantified. With the improved rates
of cure of many cancers, there is a potential for increased
numbers of individuals with CKD as a late effect of cancer
treatment.
CKD may occur after surgery for kidney cancer. Although
radical nephrectomy has been the standard surgery for
localized kidney cancer for many decades, partial nephrect-
omy has been shown to be effective for the treatment kidney
tumors less than 4 cm in diameter. Recent data suggest that a
significant number of subjects with kidney cancer have CKD
before treatment and an even greater number are at risk to
develop an eGFR o60 ml/min/1.73 m2 in long-term follow-
up after nephrectomy for cancer.75 In contrast to kidney
donors, patients with kidney cancer are an older patient
population, often with coexistent hypertension and other
chronic diseases, which may be risk factors for development
of CKD following nephrectomy. Consequently, for small,
incidentally discovered kidney tumors, partial nephrectomy
may be indicated even in patients without CKD.
CKD was also considered as a risk factor for cancer.
Occurrence of cancers in subjects with CKD is well
documented for kidney and bladder cancer.76 Acquired cysts
and kidney cancers are especially frequent in subjects on
long-term dialysis but also occur before the start of dialysis,77
and the growing number of kidney transplant candidates may
require screening for native kidney cancers.78 Kidney
transplantation itself is associated with susceptibility to
cancers,79 mainly skin cancers and lymphomas, which appear
to be related to immunosuppression rather than to reduced
kidney function.
Data from the USA showed a 30% prevalence of past or
present cancer in subjects starting dialysis, which was 50%
higher than that of a matched non-dialysis Medicare
population, and could not be explained by bladder or kidney
cancers alone.80 It is possible that risk factors common to
both cancer and kidney disease, such as smoking, diabetes
and obesity, may account for this apparently high prevalence
of cancers at the start of dialysis. Screening for cancer in
patients with end-stage renal disease has been evaluated using
decision analysis. Screening for common cancers, such as
breast or colon, had a very low yield and was not
recommended.81 This is likely due to the competing risks
for increased mortality in dialysis patients. In subjects with
earlier stages of CKD, quantitative analyses of the benefits of
cancer screening are not known.
The potential for CKD as a risk factor for adverse
outcomes of cancer and its treatment was also considered.
This may be evident in some conditions such as multiple
myeloma but is less well established in solid tumors. Analysis
of a large database from Japan showed no increase in gastric,
lung, or colon cancer mortality for subjects with eGFR
o60 ml/min/1.73 m2 compared with those with higher
eGFR.82 In the Cardiovascular Health Study, a longitudinal
study of older people in the USA, a significant trend toward
increased mortality from cancer was reported in those
subjects in the highest quartile of cystatin C values.21 One
intriguing study reported a possible lowering of cancer risk by
use of converting-enzyme inhibitors.83 Proteinuria has been
linked with poor outcome in some studies of lymphoproli-
ferative and solid malignancies.84 Most current phase 3 trials
of cancer treatments exclude subjects with impaired kidney
function. Thus, comparative data are scarce. In one study, the
response rates to capecitabine or 5-fluorouracil in subjects
with metastatic colorectal cancer did not differ according to
estimated creatinine clearance.85 In other studies, dose
adjustment of carboplatin according to kidney function, and
not body surface area, greatly improved prediction of drug
levels and toxicity.86 Newer agents, including biologicals or
radionuclides, may have unsuspected kidney toxicity that can
only be detected by regular testing. More regular assessment
of kidney function is needed in subjects with cancer. In the
USA, the National Cancer Institute (NCI) Organ Dysfunction
Working Group may facilitate additional studies of cancer in
patients with CKD. Communication among physicians,
researchers and public health officials could be improved by
harmonizing the classification of severity of CKD with the
KDIGO classification.
Recommendations
K All cancer patients should be screened for CKD at diagnosis,
at initiation, and change of cancer therapy. Tests for CKD
should include (1) a urinalysis (for hematuria and
Table 9 | Proposed approach to CKD as a risk factor for adverse outcomes of cancer
Cancer type
Measure of CKD
prevalence
CKD as a risk factor for
cancer morbidity
CKD as a risk factor for
cancer mortality
Kidney and urinary tract tumors Yes: Probable: Probable:
k eGFR75 Effect on chemotherapy k k eGFR69
ESRD status76,77 eGFR69 ESRD status76,77
Other solid tumors Possible:85,88 Probable: Albuminuria84
k eGFR85 Effect on chemotherapy Reduced risk with ACE
ESRD status88 k eGFR85 inhibitor treatment for CKD83
Hematologic malignancies Unknown Likely but unknown Albuminuria89
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; k, decreased.
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proteinuria) and (2) a measure of kidney function (serum
creatinine to estimate GFR).
K Kidney sparing interventions should be utilized in patients
with kidney and uroepithelial cancers.
K Screening for CKD is recommended in subjects cured of
cancer who are at risk for CKD, because of the type of
cancer, its complications, its treatment, or other risk factors
for CKD not related to cancer.
Research recommendations
K Cancer institutes and associations should use KDIGO
definition and staging of CKD in guidelines and recom-
mendations for detection, evaluation and treatment of
cancer.
K Evaluate the accuracy of GFR estimating equations in
cancer patients, with a particular focus on reducing the
influence of confounding factors such as muscle wasting,
malnutrition, and extracellular fluid volume expansion.
K Include CKD patients in clinical trials of cancer treatment.
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